Anavex Life Sciences Corp. (AVXL) Receives Buy Rating from Maxim Group
Separately, FBR & Co reaffirmed an outperform rating and set a $10.00 target price on shares of Anavex Life Sciences Corp. in a report on Wednesday, October 5th.
Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) opened at 4.00 on Tuesday. Anavex Life Sciences Corp. has a 1-year low of $2.43 and a 1-year high of $8.30. The firm has a 50-day moving average of $3.23 and a 200 day moving average of $3.99. The company’s market capitalization is $142.84 million.
COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the propert of of Daily Political. If you are viewing this report on another publication, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this report can be read at http://www.dailypolitical.com/2016/11/30/anavex-life-sciences-corp-avxl-receives-buy-rating-from-maxim-group.html.
Several hedge funds have recently made changes to their positions in AVXL. BlackRock Fund Advisors boosted its stake in shares of Anavex Life Sciences Corp. by 15,563.2% in the second quarter. BlackRock Fund Advisors now owns 849,417 shares of the company’s stock worth $5,190,000 after buying an additional 843,994 shares during the period. BlackRock Institutional Trust Company N.A. purchased a new stake in shares of Anavex Life Sciences Corp. during the second quarter worth about $1,739,000. Northern Trust Corp boosted its stake in shares of Anavex Life Sciences Corp. by 219.9% in the third quarter. Northern Trust Corp now owns 361,088 shares of the company’s stock worth $1,310,000 after buying an additional 248,221 shares during the period. Vanguard Group Inc. boosted its stake in shares of Anavex Life Sciences Corp. by 16.4% in the second quarter. Vanguard Group Inc. now owns 1,169,013 shares of the company’s stock worth $7,143,000 after buying an additional 164,686 shares during the period. Finally, BlackRock Investment Management LLC purchased a new stake in shares of Anavex Life Sciences Corp. during the second quarter worth about $776,000. 12.83% of the stock is owned by hedge funds and other institutional investors.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.